USFDAJun 11, 2026, 08:31 AM
Spectral AI to Showcase FDA-Approved DeepView System at BBA Meeting
AI Summary
Spectral AI announced its participation in the British Burn Association (BBA) Annual Meeting, where its DeepView System will be on display and featured in presentations. The DeepView System recently received FDA De Novo Classification in May 2026 and initial UKCA authorization in February 2024. The company expects to generate its first commercial sales of the DeepView System by year-end 2026, aiming to elevate its profile and demonstrate efficacy in burn wound assessment.
Key Highlights
- DeepView System received FDA De Novo Classification in May 2026.
- DeepView System received initial UKCA authorization in February 2024.
- Company expects first commercial sales of DeepView System by year-end 2026.
- Spectral AI will showcase DeepView System at British Burn Association Annual Meeting (June 17-19, 2026).
- DeepView System assesses burn wounds unlikely to heal within 21 days.
- Image acquisition takes 0.2 seconds; processing and AI classification takes 20-25 seconds.
Price Impact
More from MDAI